CD274 and small cell lung carcinoma: The phase III randomized controlled ETER701 study demonstrated that the anti-angiogenic agent anlotinib, when combined with the PD-L1 inhibitor benmelstobart and chemotherapy regimen of etoposide plus carboplatin, significantly prolonged median PFS to 6.9 months and median OS to 19.3 months in patients with extensive-stage SCLC (24).